Recently, another “Sodium Hyaluronate Eye Drops” product developed by our company’s controlling subsidiary, Huonland, has received the “Drug Registration Certificate” approved and issued by the National Medical Products Administration. The approval number is: National Drug Approval No. H20233631. This product is classified as a Category 4 chemical drug, with a specification of 0.1% (0.4 ml: 0.4 mg). Its primary indication is dry eye syndrome.

Dry eye syndrome, previously known as “keratoconjunctival dryness,” is a common ocular surface disorder that currently significantly impairs vision and quality of life. According to relevant statistical data, in 2020, the number of dry eye patients in China reached 240 million. With the prolonged use of smartphones and computers, as well as factors such as air pollution, the number of dry eye patients is showing a sharp upward trend.

Sodium hyaluronate eye drops are first-line medications for the treatment of dry eye syndrome. According to a report from the ophthalmic pharmaceutical industry, sodium hyaluronate ophthalmic formulations represent the largest product category in the dry eye disease drug market, accounting for over 25% of the market share. Data from PDB show that sodium hyaluronate eye drops achieved a compound annual growth rate of 17.6% during the period from 2015 to 2021, with the 0.1% dosage form continuing to hold the largest share of the sodium hyaluronate market.

The sodium hyaluronate eye drops recently approved are a single-dose, pre-dispensed product with a concentration of 0.1%. They are manufactured using the most advanced “blow-fill-seal” (BFS) production technology currently available. No preservatives added; use once after opening. It can avoid secondary contamination and reduce corneal damage caused by long-term use, making it more comfortable and safer for clinical use. As of now, the Group has obtained approval for a total of six ophthalmic products, covering a wide range of indications including dry eye syndrome, glaucoma, anti-allergy treatments, antibacterial agents, and balanced salt solutions for ocular surgery (for irrigation purposes). Specifically for dry eye syndrome, the company has developed multiple product varieties and recently received registration certificates for two sodium hyaluronate eye drop products, with specifications designed for multi-dose use. 0.1% (5 ml: 5 mg) and single dose 0.1% (0.4 ml: 0.4 mg)—the existing dexamethasone sodium eye drops are currently under review, while cyclosporine eye drops are in development. This multi-product, single-formulation strategy allows us to meet the diverse medication needs of different patient populations and provide a comprehensive treatment approach for dry eye syndrome.

The successful approval of this product once again underscores the company’s R&D capabilities in the field of ophthalmic medications and further enriches the company’s pipeline of ophthalmic products. After 10 years of development, the holding subsidiary Huiren Land has seen its performance in the ophthalmic pharmaceutical business improve steadily year after year. Meanwhile, to ensure both drug production and market supply, Huiren Land is planning to introduce a new production line and intends to make additional investments not exceeding 30 million yuan for the purchase of single-dose production equipment and related supporting facilities. Once operational, the new line is expected to achieve an annual output of 110 million units, significantly boosting the company’s capacity for eye drops. This will further strengthen the company’s competitive edge and market position in the ophthalmic pharmaceutical sector, driving continued growth in its financial performance.

The company will uphold its corporate mission of “Creating Value, Serving Health,” leverage the resource-sharing advantages of the group company, accelerate the R&D of bioengineered pharmaceuticals, and continuously expand and strengthen its ophthalmology business. In doing so, we will provide the public with more safe, effective, and high-quality medications, thereby achieving healthy, stable, and high-quality development for the company.